Renalytix plc
("Renalytix" or the
"Company")
Change of Adviser
LONDON and NEW YORK,
30 August 2024 - Renalytix plc (NASDAQ:
RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro
diagnostics company, focused on optimizing clinical management of
kidney disease to drive improved patient outcomes and advance
value-based care, announces that with the previously
announced appointment of Oberon Capital (a trading name
of Oberon Investments Limited) as joint broker on August
21st concurrent with Stifel Nicolaus Europe Limited
("Stifel"), that Investec Bank plc is ceasing to act as Joint
Broker with effect from 31 August 2024. Stifel will continue to act
as Nominated Adviser.
For further information,
please contact:
Renalytix plc
|
www.renalytix.com
|
James McCullough, CEO
|
Via
Walbrook PR
|
|
|
Stifel (Nominated Adviser and Joint Broker)
|
Tel: 020
7710 7600
|
Nicholas Moore / Nick Harland / Ben
Good
|
|
|
|
Oberon Capital
(Joint Broker)
|
Tel: 020
3179 5300
|
Mike Seabrook / Nick Lovering
|
|
|
|
Walbrook PR Limited
|
Tel: 020
7933 8780 or renalytix@walbrookpr.com
|
Paul McManus / Alice Woodings / Charlotte Edgar
|
Mob: 07980 541 893 / 07407
804 654 / 07884 664 686
|
|
|
CapComm Partners
|
|
Peter DeNardo
|
Tel:
415-389-6400 or investors@renalytix.com
|
About
Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro
diagnostics and laboratory services company that is the global
founder and leader in the new field of bioprognosis™ for kidney
health. The leadership team, with a combined 200+ years of
healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment
for rapid progressive decline in kidney function in adult patients
with T2D and early CKD (stages 1-3). We believe that by
understanding how disease will progress, patients and providers can
take action early to improve outcomes and reduce overall health
system costs. For more information, visit www.renalytix.com.
Important Notices
Stifel Nicolaus Europe Limited and
Oberon Investments Limited are authorised and regulated in
the United Kingdom by the Financial Conduct Authority
("FCA") and are acting exclusively for the Company and for no one
else in connection with the subject matter of this announcement and
will not be responsible to anyone other than Renalytix for
providing the protections afforded to its clients nor for providing
advice in relation to the subject matter of this
announcement.
This announcement is not intended
to, and does not, constitute or form part of any offer, invitation
or the solicitation of an offer to purchase, otherwise acquire,
subscribe for, sell or otherwise dispose of, any securities whether
pursuant to this announcement or otherwise.
This announcement (including any
information incorporated by reference in this announcement) and
other information published by the Company contain statements about
the Company that are or may be deemed to be forward looking
statements. Without limitation, any statements preceded or followed
by or that include the words "targets", "plans", "believes",
"expects", "aims", "intends", "will", "may", "anticipates",
"estimates", "projects" or words or terms of similar substance or
the negative thereof, may be forward looking statements.
These forward-looking statements are
not guarantees of future performance. Such forward-looking
statements involve known and unknown risks and uncertainties that
could significantly affect expected results and are based on
certain key assumptions. Many factors could cause actual results to
differ materially from those projected or implied in any
forward-looking statements. Due to such uncertainties and risks,
readers should not rely on such forward-looking statements, which
speak only as of the date of this announcement. The Company
disclaims any obligation or responsibility to update publicly or
review any forward-looking or other statements contained in this
announcement, except as required by applicable law.
The distribution of this
announcement in jurisdictions outside the United
Kingdom may be restricted by law and therefore persons into
whose possession this announcement comes should inform themselves
about, and observe, such restrictions. Any failure to comply with
the restrictions may constitute a violation of the securities law
of any such jurisdiction.